Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

Capricor faces sharp regulatory setbacks, a 64% stock collapse, and legal scrutiny.

What the company is saying

The announcement communicates that Capricor Therapeutics, Inc. is under investigation by Lowey Dannenberg P.C. for potential violations of federal securities laws. It highlights that, on July 27, 2026, Capricor disclosed the FDA used an outdated statistical analysis plan (SAP version 1.1) in its briefing materials, rather than the final SAP version 3.0 that Capricor claims governed its Phase 3 HOPE-3 trial results. The company frames the outdated SAP as an unsigned, incomplete draft, suggesting a disconnect between the FDA's review and Capricor's intended submission. The narrative emphasizes the negative impact of this regulatory confusion, including a 64% drop in share price and the loss of hundreds of millions in shareholder value. The announcement also details a 3-9 negative vote by the FDA Advisory Committee regarding the effectiveness of Deramiocel for cardiomyopathy in DMD, further undermining confidence in the regulatory process. The tone is factual but negative, with no attempt to minimize the seriousness of the regulatory and legal challenges.

What the data suggests

The numbers reveal a severe deterioration in Capricor's financial and regulatory position. The stock price fell approximately 64% after the July 27, 2026 disclosure, erasing hundreds of millions in market capitalization. The FDA Advisory Committee's 3-9 vote against the effectiveness of Deramiocel for cardiomyopathy in DMD signals a major setback for the company's lead asset. The vote addressed a narrower indication than Capricor had sought, indicating the regulatory pathway is more challenging than anticipated. The only forward-looking milestone is the August 22, 2026 PDUFA target action date, but the negative advisory vote casts doubt on a favorable outcome. No financial metrics beyond the share price decline are disclosed, and there is no evidence of offsetting operational or commercial progress. The data is sparse, with key financial and operational details omitted, but what is present points to a rapidly worsening outlook.

Analysis

The announcement is factual and negative, focusing on regulatory setbacks, a sharp stock price decline, and the initiation of a legal investigation. There is no promotional or exaggerated language; the tone is somber and centers on realised events, such as the 64% stock price drop and the negative FDA Advisory Committee vote. Only one claim is forward-looking, referencing the upcoming FDA PDUFA action date, but this is presented as a factual timeline rather than an aspirational projection. No large capital outlay or future benefit is discussed, and there is no attempt to frame the situation positively or inflate the company's prospects. The data supports a deteriorating outlook, with no evidence of hype or narrative inflation.

Risk flags

• ●Regulatory risk is acute, as the FDA Advisory Committee voted 9-3 against the effectiveness of Capricor's lead asset, Deramiocel, for its proposed indication. This significantly reduces the likelihood of approval and undermines the company's core value proposition.
• ●Disclosure risk is elevated due to the company's admission that the FDA relied on a superseded, incomplete statistical analysis plan, raising questions about the clarity and completeness of Capricor's regulatory submissions.
• ●Financial risk is high following a 64% collapse in share price and the loss of hundreds of millions in shareholder value, which may impair access to capital and threaten ongoing operations.
• ●Legal risk is present, as Lowey Dannenberg P.C. has initiated an investigation into potential securities law violations, increasing the possibility of litigation, financial penalties, or further reputational damage.

Bottom line

This announcement signals a crisis for Capricor, with a catastrophic 64% share price drop, a negative FDA Advisory Committee vote, and a legal investigation all converging within days. The company's explanation that the FDA relied on an outdated statistical analysis plan does little to restore confidence, especially given the lack of detailed financial or operational disclosures. The upcoming FDA PDUFA action date offers a narrow window for potential reversal, but the negative advisory vote makes approval unlikely. Investors face immediate and severe downside risk, with no clear evidence of a turnaround or mitigating developments. The most important takeaway is that Capricor's lead asset and investment case are now in serious jeopardy, and the company must provide clear, detailed disclosures and a credible regulatory path forward to regain market trust.

Announcement summary

(NASDAQ: CAPR) Capricor Therapeutics, Inc. is being investigated by Lowey Dannenberg P.C. for potential violations of the federal securities laws. On July 27, 2026, Capricor disclosed that the FDA’s briefing materials relied on a superseded statistical analysis, specifically Statistical Analysis Plan (“SAP”) version 1.1, rather than the final SAP version 3.0 that Capricor says governed its reported Phase 3 HOPE-3 trial results. Following this news, the price of Capricor stock fell approximately 64%, wiping out hundreds of millions of dollars in shareholder value. On July 30, 2026, Capricor announced that the FDA Advisory Committee had voted 3 in favor and 9 against finding that the available evidence supports the effectiveness of Deramiocel for treating cardiomyopathy in DMD. The vote is non-binding and addressed a narrower cardiomyopathy indication than Capricor had proposed, raising new doubts about the BLA ahead of the FDA’s August 22, 2026 PDUFA target action date. The investigation concerns whether the company and its executives provided investors with accurate and complete information about the company.

Disagree with this article?